Loading…

Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil

S-1 is an oral formulation combining tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. We examined whether Oxo reduces the immunosuppression induced by 5-fluorouracil (5-FU) in the rat. The body weight of rats treated with S-1 (FT + CDHP +...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2006-08, Vol.58 (2), p.183-188
Main Authors: YAMASHITA, Tetsuro, UEDA, Yuji, FUJI, Nobuaki, ITOH, Tsuyoshi, KURIOKA, Hideaki, SHIRASAKA, Tetsuhiko, YAMAGISHI, Hisakazu
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-ea6f37734de7a2acb955c1d1ca07752424b8e381e6b80486b73fa35e45104ee43
cites cdi_FETCH-LOGICAL-c356t-ea6f37734de7a2acb955c1d1ca07752424b8e381e6b80486b73fa35e45104ee43
container_end_page 188
container_issue 2
container_start_page 183
container_title Cancer chemotherapy and pharmacology
container_volume 58
creator YAMASHITA, Tetsuro
UEDA, Yuji
FUJI, Nobuaki
ITOH, Tsuyoshi
KURIOKA, Hideaki
SHIRASAKA, Tetsuhiko
YAMAGISHI, Hisakazu
description S-1 is an oral formulation combining tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. We examined whether Oxo reduces the immunosuppression induced by 5-fluorouracil (5-FU) in the rat. The body weight of rats treated with S-1 (FT + CDHP + Oxo) for seven consecutive days was significantly higher than that of rats treated with a combination of FT plus CDHP (FT + CDHP) for a similar period. The number of peripheral leukocytes was significantly higher in the S-1-treated rats (S-1 group) than that in the FT + CDHP-treated rats (FT + CDHP group). There was no apparent difference between the two treated groups in phenotypic changes of CD3-, CD45-, CD4-, or CD8-positive cells from the spleen or mesenteric lymph nodes. However, the natural killer activities of both spleen cells and mesenteric lymph node cells were significantly higher in the S-1 group than in the FT + CDHP group. Interleukin (IL)-2 production by spleen cells stimulated with concanavalin A was significantly lower in the FT + CDHP group than in the S-1 group. Although IL-2 production by mesenteric lymph node cells in the S-1 group was lower than that in untreated rats, it was higher than that in the FT + CDHP group. These findings suggest that Oxo in S-1 may reduce the suppression of antitumor immunity induced by 5-FU.
doi_str_mv 10.1007/s00280-005-0150-0
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67911732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67911732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-ea6f37734de7a2acb955c1d1ca07752424b8e381e6b80486b73fa35e45104ee43</originalsourceid><addsrcrecordid>eNpdkV1rFTEQhoMo9rT6A7yRINirrk42yWZ7WYpfUFBQr0M2O0tTNsmaD_B45z83h3Og4NUMw_O-DDyEvGLwjgGo9xmgH6EDkB0w2ZYnZMcE7zsYBX9KdsCF6KQCcUbOc34AAME4f07O2MCZklLtyN9vsZicXfU0_o7BFLyiJlAMf_YeqQv3bnIlJmqj32INM87tSL937IomnKvFTMs90ly3LWHriYHGpTUUV6pvOed9Da7sW-pAz3TaU9kta40p1mSsW1-QZ4tZM748zQvy8-OHH7efu7uvn77c3tx1lsuhdGiGhSvFxYzK9MZO11JaNjNrQCnZi15MI_KR4TCNIMZhUnwxXKKQDASi4Bfk8ti7pfirYi7au2xxXU3AWLMe1DVjivcNfPMf-NBeDe033TMuxThK2SB2hGyKOSdc9JacN2mvGeiDHH2Uo5scfZCjoWVen4rr5HF-TJxsNODtCTDZmnVJJliXHzmlVN9zxf8BUIKYIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213548855</pqid></control><display><type>article</type><title>Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil</title><source>Springer Nature</source><creator>YAMASHITA, Tetsuro ; UEDA, Yuji ; FUJI, Nobuaki ; ITOH, Tsuyoshi ; KURIOKA, Hideaki ; SHIRASAKA, Tetsuhiko ; YAMAGISHI, Hisakazu</creator><creatorcontrib>YAMASHITA, Tetsuro ; UEDA, Yuji ; FUJI, Nobuaki ; ITOH, Tsuyoshi ; KURIOKA, Hideaki ; SHIRASAKA, Tetsuhiko ; YAMAGISHI, Hisakazu</creatorcontrib><description>S-1 is an oral formulation combining tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. We examined whether Oxo reduces the immunosuppression induced by 5-fluorouracil (5-FU) in the rat. The body weight of rats treated with S-1 (FT + CDHP + Oxo) for seven consecutive days was significantly higher than that of rats treated with a combination of FT plus CDHP (FT + CDHP) for a similar period. The number of peripheral leukocytes was significantly higher in the S-1-treated rats (S-1 group) than that in the FT + CDHP-treated rats (FT + CDHP group). There was no apparent difference between the two treated groups in phenotypic changes of CD3-, CD45-, CD4-, or CD8-positive cells from the spleen or mesenteric lymph nodes. However, the natural killer activities of both spleen cells and mesenteric lymph node cells were significantly higher in the S-1 group than in the FT + CDHP group. Interleukin (IL)-2 production by spleen cells stimulated with concanavalin A was significantly lower in the FT + CDHP group than in the S-1 group. Although IL-2 production by mesenteric lymph node cells in the S-1 group was lower than that in untreated rats, it was higher than that in the FT + CDHP group. These findings suggest that Oxo in S-1 may reduce the suppression of antitumor immunity induced by 5-FU.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-005-0150-0</identifier><identifier>PMID: 16317557</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Antineoplastic agents ; Biological and medical sciences ; Drug Combinations ; Enzyme Inhibitors - pharmacology ; Fluorouracil - antagonists &amp; inhibitors ; Gastroenterology. Liver. Pancreas. Abdomen ; Immunophenotyping ; Interleukin-2 - biosynthesis ; Killer Cells, Natural - immunology ; Male ; Medical sciences ; Neoplasms, Experimental - immunology ; Oxonic Acid - pharmacology ; Pharmacology. Drug treatments ; Pyridines - pharmacology ; Rats ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tegafur - pharmacology ; Tumors</subject><ispartof>Cancer chemotherapy and pharmacology, 2006-08, Vol.58 (2), p.183-188</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer-Verlag 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-ea6f37734de7a2acb955c1d1ca07752424b8e381e6b80486b73fa35e45104ee43</citedby><cites>FETCH-LOGICAL-c356t-ea6f37734de7a2acb955c1d1ca07752424b8e381e6b80486b73fa35e45104ee43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17772237$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16317557$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YAMASHITA, Tetsuro</creatorcontrib><creatorcontrib>UEDA, Yuji</creatorcontrib><creatorcontrib>FUJI, Nobuaki</creatorcontrib><creatorcontrib>ITOH, Tsuyoshi</creatorcontrib><creatorcontrib>KURIOKA, Hideaki</creatorcontrib><creatorcontrib>SHIRASAKA, Tetsuhiko</creatorcontrib><creatorcontrib>YAMAGISHI, Hisakazu</creatorcontrib><title>Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>S-1 is an oral formulation combining tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. We examined whether Oxo reduces the immunosuppression induced by 5-fluorouracil (5-FU) in the rat. The body weight of rats treated with S-1 (FT + CDHP + Oxo) for seven consecutive days was significantly higher than that of rats treated with a combination of FT plus CDHP (FT + CDHP) for a similar period. The number of peripheral leukocytes was significantly higher in the S-1-treated rats (S-1 group) than that in the FT + CDHP-treated rats (FT + CDHP group). There was no apparent difference between the two treated groups in phenotypic changes of CD3-, CD45-, CD4-, or CD8-positive cells from the spleen or mesenteric lymph nodes. However, the natural killer activities of both spleen cells and mesenteric lymph node cells were significantly higher in the S-1 group than in the FT + CDHP group. Interleukin (IL)-2 production by spleen cells stimulated with concanavalin A was significantly lower in the FT + CDHP group than in the S-1 group. Although IL-2 production by mesenteric lymph node cells in the S-1 group was lower than that in untreated rats, it was higher than that in the FT + CDHP group. These findings suggest that Oxo in S-1 may reduce the suppression of antitumor immunity induced by 5-FU.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Drug Combinations</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fluorouracil - antagonists &amp; inhibitors</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Immunophenotyping</subject><subject>Interleukin-2 - biosynthesis</subject><subject>Killer Cells, Natural - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasms, Experimental - immunology</subject><subject>Oxonic Acid - pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pyridines - pharmacology</subject><subject>Rats</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tegafur - pharmacology</subject><subject>Tumors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNpdkV1rFTEQhoMo9rT6A7yRINirrk42yWZ7WYpfUFBQr0M2O0tTNsmaD_B45z83h3Og4NUMw_O-DDyEvGLwjgGo9xmgH6EDkB0w2ZYnZMcE7zsYBX9KdsCF6KQCcUbOc34AAME4f07O2MCZklLtyN9vsZicXfU0_o7BFLyiJlAMf_YeqQv3bnIlJmqj32INM87tSL937IomnKvFTMs90ly3LWHriYHGpTUUV6pvOed9Da7sW-pAz3TaU9kta40p1mSsW1-QZ4tZM748zQvy8-OHH7efu7uvn77c3tx1lsuhdGiGhSvFxYzK9MZO11JaNjNrQCnZi15MI_KR4TCNIMZhUnwxXKKQDASi4Bfk8ti7pfirYi7au2xxXU3AWLMe1DVjivcNfPMf-NBeDe033TMuxThK2SB2hGyKOSdc9JacN2mvGeiDHH2Uo5scfZCjoWVen4rr5HF-TJxsNODtCTDZmnVJJliXHzmlVN9zxf8BUIKYIw</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>YAMASHITA, Tetsuro</creator><creator>UEDA, Yuji</creator><creator>FUJI, Nobuaki</creator><creator>ITOH, Tsuyoshi</creator><creator>KURIOKA, Hideaki</creator><creator>SHIRASAKA, Tetsuhiko</creator><creator>YAMAGISHI, Hisakazu</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20060801</creationdate><title>Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil</title><author>YAMASHITA, Tetsuro ; UEDA, Yuji ; FUJI, Nobuaki ; ITOH, Tsuyoshi ; KURIOKA, Hideaki ; SHIRASAKA, Tetsuhiko ; YAMAGISHI, Hisakazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-ea6f37734de7a2acb955c1d1ca07752424b8e381e6b80486b73fa35e45104ee43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Drug Combinations</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fluorouracil - antagonists &amp; inhibitors</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Immunophenotyping</topic><topic>Interleukin-2 - biosynthesis</topic><topic>Killer Cells, Natural - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasms, Experimental - immunology</topic><topic>Oxonic Acid - pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pyridines - pharmacology</topic><topic>Rats</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tegafur - pharmacology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YAMASHITA, Tetsuro</creatorcontrib><creatorcontrib>UEDA, Yuji</creatorcontrib><creatorcontrib>FUJI, Nobuaki</creatorcontrib><creatorcontrib>ITOH, Tsuyoshi</creatorcontrib><creatorcontrib>KURIOKA, Hideaki</creatorcontrib><creatorcontrib>SHIRASAKA, Tetsuhiko</creatorcontrib><creatorcontrib>YAMAGISHI, Hisakazu</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YAMASHITA, Tetsuro</au><au>UEDA, Yuji</au><au>FUJI, Nobuaki</au><au>ITOH, Tsuyoshi</au><au>KURIOKA, Hideaki</au><au>SHIRASAKA, Tetsuhiko</au><au>YAMAGISHI, Hisakazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>58</volume><issue>2</issue><spage>183</spage><epage>188</epage><pages>183-188</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>S-1 is an oral formulation combining tegafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo) in a molar ratio of 1:0.4:1. We examined whether Oxo reduces the immunosuppression induced by 5-fluorouracil (5-FU) in the rat. The body weight of rats treated with S-1 (FT + CDHP + Oxo) for seven consecutive days was significantly higher than that of rats treated with a combination of FT plus CDHP (FT + CDHP) for a similar period. The number of peripheral leukocytes was significantly higher in the S-1-treated rats (S-1 group) than that in the FT + CDHP-treated rats (FT + CDHP group). There was no apparent difference between the two treated groups in phenotypic changes of CD3-, CD45-, CD4-, or CD8-positive cells from the spleen or mesenteric lymph nodes. However, the natural killer activities of both spleen cells and mesenteric lymph node cells were significantly higher in the S-1 group than in the FT + CDHP group. Interleukin (IL)-2 production by spleen cells stimulated with concanavalin A was significantly lower in the FT + CDHP group than in the S-1 group. Although IL-2 production by mesenteric lymph node cells in the S-1 group was lower than that in untreated rats, it was higher than that in the FT + CDHP group. These findings suggest that Oxo in S-1 may reduce the suppression of antitumor immunity induced by 5-FU.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>16317557</pmid><doi>10.1007/s00280-005-0150-0</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-5704
ispartof Cancer chemotherapy and pharmacology, 2006-08, Vol.58 (2), p.183-188
issn 0344-5704
1432-0843
language eng
recordid cdi_proquest_miscellaneous_67911732
source Springer Nature
subjects Animals
Antineoplastic agents
Biological and medical sciences
Drug Combinations
Enzyme Inhibitors - pharmacology
Fluorouracil - antagonists & inhibitors
Gastroenterology. Liver. Pancreas. Abdomen
Immunophenotyping
Interleukin-2 - biosynthesis
Killer Cells, Natural - immunology
Male
Medical sciences
Neoplasms, Experimental - immunology
Oxonic Acid - pharmacology
Pharmacology. Drug treatments
Pyridines - pharmacology
Rats
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tegafur - pharmacology
Tumors
title Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A33%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potassium%20oxonate,%20an%20enzyme%20inhibitor%20compounded%20in%20S-1,%20reduces%20the%20suppression%20of%20antitumor%20immunity%20induced%20by%205-fluorouracil&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=YAMASHITA,%20Tetsuro&rft.date=2006-08-01&rft.volume=58&rft.issue=2&rft.spage=183&rft.epage=188&rft.pages=183-188&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-005-0150-0&rft_dat=%3Cproquest_cross%3E67911732%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-ea6f37734de7a2acb955c1d1ca07752424b8e381e6b80486b73fa35e45104ee43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213548855&rft_id=info:pmid/16317557&rfr_iscdi=true